Free Trial

Charles Schwab Investment Management Inc. Grows Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Syndax Pharmaceuticals logo with Medical background

Charles Schwab Investment Management Inc. raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 6.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 695,947 shares of the company's stock after acquiring an additional 41,458 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.82% of Syndax Pharmaceuticals worth $13,397,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in Syndax Pharmaceuticals in the 3rd quarter valued at about $429,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $15,165,000. First Turn Management LLC boosted its position in Syndax Pharmaceuticals by 85.4% during the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock worth $22,853,000 after acquiring an additional 546,776 shares during the last quarter. Quest Partners LLC boosted its position in Syndax Pharmaceuticals by 31.0% during the third quarter. Quest Partners LLC now owns 17,858 shares of the company's stock worth $344,000 after acquiring an additional 4,223 shares during the last quarter. Finally, Simplify Asset Management Inc. grew its stake in Syndax Pharmaceuticals by 62.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company's stock worth $2,352,000 after acquiring an additional 46,992 shares during the period.

Analyst Ratings Changes

Several research firms have recently issued reports on SNDX. StockNews.com cut Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. The Goldman Sachs Group raised their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. HC Wainwright upped their price objective on shares of Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a "buy" rating in a research note on Monday, November 18th. Stifel Nicolaus raised their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Finally, UBS Group began coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $37.64.

View Our Latest Analysis on SNDX

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock traded down $1.45 during trading hours on Monday, reaching $15.56. The company had a trading volume of 2,578,967 shares, compared to its average volume of 1,173,873. Syndax Pharmaceuticals, Inc. has a twelve month low of $15.00 and a twelve month high of $25.34. The stock's fifty day simple moving average is $18.29 and its 200 day simple moving average is $19.65.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the business earned ($0.73) EPS. On average, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

See Also

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Should you invest $1,000 in Syndax Pharmaceuticals right now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

AVGO is up 30% since earnings: could Broadcom be the next member of the Magnificent Seven? Can it sustain this momentum or is a pullback on the horizon?

Related Videos

Why Meta Is Still a Top Stock Pick for 2025
Meta Platforms Tops Most Upgraded Stocks List—Here’s What to Expect
Alphabet Gaining Momentum: Can It Reach $200 by December?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines